Please assess the completion status of the following clinical trial:

Trial Title: Antioxidant Supplement and Reduction of Metachronous Adenomas of the Large Bowel: a Double Blind Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 25-75 years~* at least one histologically confirmed adenoma endoscopically removed from the large bowel resulting in a polyp-free colon-rectum (clean colon).~Exclusion Criteria:~* polypectomy performed more than 6 months before enrolment in the trial~* history of Familial Adenomatous Polyposis~* inflammatory bowel disease~* adenoma with invasive carcinoma~* ten or more adenomas~* large sessile adenoma (3 cm or more~* colorectal resection~* invasive cancer at any site~* life-threatening and/or chronic heart, liver or kidney diseases~* current use of vitamin or calcium supplements~* mental disability

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- antioxidants (Type: EXPERIMENTAL): tablets composed of 200 mcg selenium \[as l-selenomethionine\], 30 mg zinc, 2 mg vitamin A \[retinol\], 180 mg vitamin C \[ascorbic acid\] and 30 mg vitamin E \[D-α-tocopherol acetate\]
- Sugar pill (Type: PLACEBO_COMPARATOR): placebo had an identical appearance as intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).